Trypsin activity is not involved in premature, intrapancreatic trypsinogen activation.
A premature and intracellular activation of digestive zymogens is thought to be responsible for the onset of pancreatitis. Because trypsin has a critical role in initiating the activation cascade of digestive enzymes in the gut, it has been assumed that trypsin also initiates intracellular zymogen activation in the pancreas. We have tested this hypothesis in isolated acini and lobules from rat pancreas. Intracellular trypsinogen activation was induced by supramaximal secretagogue stimulation and measured using either specific trypsin substrates or immunoreactivity of the trypsinogen activation peptide (TAP). To prevent a trypsin-induced trypsinogen activation, we used the cell-permeant, highly specific, and reversible inhibitor Nalpha-(2-naphthylsulfonyl)-3-amidinophenylalanine-carboxymethylpiperazide (S124), and to prevent cathepsin-induced trypsinogen activation, we used the cysteine protease inhibitor E-64d. Incubation of acini or lobules in the presence of S124 completely prevented the generation of trypsin activity in response to supramaximal caerulein but had no effect whatsoever on the generation of TAP. Conversely, when trypsin activity was recovered at the end of the experiment by either washout of S124 from acini or extensive dilution of lobule homogenates, it was up to 400% higher than after caerulein alone and corresponded, in molar terms, to the generation of TAP. Both trypsin activity and TAP release were inhibited in parallel by E-64d. We conclude that caerulein-induced trypsinogen activation in the pancreas is caused by an E-64d-inhibitable mechanism such as cathepsin-induced trypsinogen activation, and neither involves nor requires intracellular trypsin activity. Specific trypsin inhibition, on the other hand, prevents 80% of trypsin inactivation or autodegradation in the pancreas.
Halangk
Walter
W
Division of Experimental Surgery, Department of Surgery, Otto-von-Guericke-Universität, 39120 Magdeburg, Germany.
Krüger
Burkhard
B
Ruthenbürger
Manuel
M
Stürzebecher
Jörg
J
Albrecht
Elke
E
Lippert
Hans
H
Lerch
Markus M
MM
D000208:Acute Disease; D000818:Animals; D002401:Cathepsin B / Q000378:metabolism; D002108:Ceruletide / Q000494:pharmacology; D004789:Enzyme Activation / Q000502:physiology; D008297:Male; D009281:Naphthalenes / Q000494:pharmacology; D010179:Pancreas / Q000201:enzymology*; D010195:Pancreatitis / Q000378:metabolism*; D010879:Piperazines / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D014357:Trypsin / Q000378:metabolism*; D014361:Trypsin Inhibitors / Q000494:pharmacology; D014362:Trypsinogen / Q000378:metabolism*
C448907:Nalpha-(2-naphthylsulfonyl)-3-amidinophenylalanine-carboxymethylpiperazide; D009281:Naphthalenes; D010879:Piperazines; D014361:Trypsin Inhibitors; D002108:Ceruletide; D014362:Trypsinogen; D014357:Trypsin; D002401:Cathepsin B